Implantable scaffolds to make CAR‑T therapy stronger and cheaper for brain tumors
Official title: Bioinstructive Scaffolds for Potent and Affordable CAR-T Cell Therapy Against Brain Tumors
Funded at Univ of North Carolina Chapel Hill · NIH-11294220 · Data updated 2026-11-12
This project aims to use a biocompatible implant placed at the tumor site to help CAR‑T immune cells reach and kill glioblastoma cells while reducing the need for repeated, costly infusions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | August 27, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2026 |
| Award (this year) | $634,205 |
| NIH project number | 5R01CA278961-04 |
| Project ID | NIH-11294220 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with glioblastoma who are undergoing tumor resection and could receive local delivery of CAR‑T cells into the resection cavity or ventricular system.
✕Less likely to help
People with non-brain cancers, those who cannot safely undergo neurosurgery or catheter placement, or those with medical conditions preventing immunotherapy are unlikely to benefit from this approach.
What this research studies
From a patient's perspective, researchers are designing a safe, bioinstructive scaffold that can be placed into the tumor cavity during surgery to hold and support CAR‑T cells locally. The scaffold is intended to help CAR‑T cells cross barriers in the brain, resist local immunosuppression, and stay active longer so fewer doses are needed. The team will test different scaffold materials and CAR‑T combinations in the lab and in preclinical models to find the safest and most effective approach. If those results are promising, the work would move toward clinical testing at specialized medical centers.
Why it matters
Potential benefit: If successful, this could make CAR‑T treatment more effective against glioblastoma and more accessible by lowering costs and reducing repeat hospital procedures.
How similar studies have gone: CAR‑T therapy has been highly successful for some blood cancers and early CAR‑T trials in glioblastoma have shown promise, but using implantable scaffolds to sustain CAR‑T locally is a newer strategy with limited human data.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Brudno, Yevgeny — Univ of North Carolina Chapel Hill
- Study coordinator: Brudno, Yevgeny
Related research
Other NIH-funded projects on the same topics.
-
Developing new scaffolds to improve CAR-T cell therapy for brain tumors
This study is looking at a new way to make CAR-T cell therapy work better for people with glioblastoma, a tough brain tumor, by using special scaffolds to help deliver the treatment right to the tumor, so patients can get more effective care.
-
Enhancing CAR T cell therapy for brain tumors
This study is looking at ways to make CAR T cell therapy better for people with high grade gliomas, a tough type of brain tumor, by tweaking the T cells to help them fight the tumor more effectively.
-
Improving CAR-T cell therapy for brain tumors using focused ultrasound
This study is looking at how using focused ultrasound can help CAR-T cell therapy work better for people with glioblastoma, a type of brain tumor, by making it easier for the treatment to reach and attack the tumor cells in the brain.
-
ONC206 for children with brain tumors: a first-in-children trial
A first-in-children trial will test the safety and early signs of effectiveness of ONC206, taken by mouth, in kids with malignant brain tumors like diffuse midline gliomas.
-
ONC206 for children with malignant brain tumors
A first-in-children trial tests the safety and early effectiveness of a pill that can cross the brain barrier to treat pediatric brain tumors.
-
ONC206 for children with dangerous brain tumors
A first-in-children study tests the safety and early effectiveness of an oral drug, ONC206, for kids with high-risk brain tumors that have spread or recurred.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.